Good question
It does say in the announcement …
The proposed trial will explore the safety, tolerability and efficacy of a combination of narmafotinib with the chemotherapy regime FOLFIRINOX.
So Presumably not … as the wording says, explore safety tolerability and efficacy
As we know efficacy was not officially tested in the Australian phase 1b trail …
.
Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-25
Add ATX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
12.5¢ |
Change
-0.005(3.85%) |
Mkt cap ! $34.27M | |||
| Open | High | Low | Value | Volume |
| 13.0¢ | 13.0¢ | 12.0¢ | $120.7K | 983.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 279677 | 12.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 12.5¢ | 16317 | 1 |
View Market Depth
| Last trade - 15.44pm 23/08/2024 (20 minute delay) ? |
| ATX (ASX) Chart |